Program By Day

7:00 AM-8:15 AM Complimentary Continental Breakfast
7:00 AM-6:30 PM Exhibits Open
7:30 AM-8:15 AM Breakout Session: Immunology 101—The Basics

Mary L. (Nora) Disis, MD, FASCO
University of Washington
Immunology 101: The Basics

Panel Question and Answer
8:15 AM-10:00 AM Welcome and General Session 1: Pushing the Envelope With Melanoma Immunotherapy

Ann W. Silk, MD—Chair
Rutgers Cancer Institute of New Jersey

Katy K. Tsai, MD—Chair
University of California, San Francisco

Mary L. (Nora) Disis, MD, FASCO
University of Washington
Welcome

Katy K. Tsai, MD
University of California, San Francisco
Integration of Immune Checkpoint Inhibitors in Melanoma

Antoni Ribas, MD, PhD
University of California Los Angeles Medical Center
How Melanoma Resists Immune Attack and Implications for Treatment

Sunandana Chandra, MD, MS
Northwestern University
Immunotherapy to Treat Metastatic Melanoma to the Brain

Panel Question and Answer
10:00 AM-10:30 AM Break
10:30 AM-11:30 AM General Session 2: Considerations for Clinical Trial Designs

Mary L. (Nora) Disis, MD, FASCO—Chair
University of Washington

Elad Sharon, MD, MPH—Chair
National Cancer Institute

Johann S. De Bono, MD, PhD, FRCP
The Institute of Cancer Research and The Royal Marsden Hospital
Principles of Clinical Trial Design in the Era of Immunotherapy and Molecular Targets for Cancer

Shivaani Kummar, MD, FACP
Stanford University Medical Center
Trial Design for Early-Phase Testing of New Agents

Lisa H. Butterfield, PhD
University of Pittsburgh
Selection and Testing of Optimal Correlates to Immunotherapy Trials: Optional or Critical, Integrated or Integral?

Panel Question and Answer
11:30 AM-1:00 PM

Poster Session A
With Complimentary Boxed Lunch

11:30 AM-1:00 PM

Trials in Progress Poster Session A
With Complimentary Boxed Lunch

11:45 AM-12:45 PM Networking Roundtables
For more information on Networking Roundtables, please visit the Onsite Networking page.
1:00 PM-1:45 PM

Keynote Lecture

Jeffrey Bluestone, PhD
Parker Institute for Cancer Immunotherapy and University of California, San Francisco
The Future of Cancer Immunotherapy

 

Panel Question and Answer

1:45 PM-3:00 PM

Oral Abstract Session A: Clinical Trials

Ann W. Silk MD—Chair

Rutgers Cancer Institute of New Jersey

 

Johann S. De Bono, MD, PhD, FRCP—Chair
The Institute of Cancer Research and The Royal Marsden Hospital

 

Abstract 48: A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.
First author: Michael Friedlander, MD, PhD

 

Abstract 139: Whole body PD-L1 PET in patients with NSCLC and melanoma.
First author: David Leung

 

Deborah J.L Wong, MD, PhD
University of California, Los Angeles
Discussion

 

Abstract 49: Phase I study of E7046, a novel PGE2 receptor type 4 inhibitor, in patients with advanced solid tumors: Clinical results and effects on myeloid- and T-lymphoid cell-mediated immunosuppression.
First author: David Hong, MD

 

Ann W. Silk, MD
Rutgers Cancer Institute of New Jersey
Discussion

 

Panel Question and Answer

3:00 PM-3:30 PM Break
3:30 PM-5:00 PM

General Session 3: Integrating Immunotherapy Into the Management of Head and Neck Cancers

Ravindra Uppaluri, MD, PhD—Chair
Brigham and Women's Hospital and Dana-Farber Cancer Institute

Deborah J.L. Wong, MD, PhD—Chair
University of California, Los Angeles

Ezra E.W. Cohen, MD, FRCPC, FASCO
University of California, San Diego
Integration of Immune Checkpoint Inhibitors in Head and Neck Cancers

Andrew G. Sikora, MD, PhD, MRCP
Baylor College of Medicine
Overcoming the Immunosuppressive Tumor Microenvironment in Head and Neck Cancers

Marka R. Crittenden, MD, PhD
Earle A. Chiles Research Institute, Providence Cancer Center
Interplay of Radiation and Immunotherapy in Head and Neck Cancers

 

Abstract 47: Analysis of over 100,000 patients with cancer for CD274 (PD-L1)amplification: Implications for treatment with immune checkpoint blockade.
First Author: Aaron Goodman, MD

 

Abstract 20: Safety and clinical activity of pembrolizumab immunotherapy and multiorgan site ablative stereotactic body radiotherapy (iMOSART) in patients with advanced solid tumors.
First Author: Jeffrey Lemons, MD

 

Ravindra Uppaluri, MD, PhD—Chair
Brigham and Women's Hospital and Dana-Farber Cancer Institute
Discussion



Panel Question and Answer

5:00 PM-5:30 PM Evening Highlights: How Will Today’s Presentations Impact Clinical Practice?

Katy K. Tsai, MD
University of California, San Francisco
How Will Today’s Presentations Impact Clinical Practice?
5:30 PM-6:30 PM

Poster Session A, Continued
Reception with Complimentary Wine and Cheese

5:30 PM-6:30 PM Trials in Progress Poster Session A, Continued
Reception with Complimentary Wine and Cheese
5:45 PM-6:30 PM

Poster Walks
Open to all attendees. Meet at the Poster Assistance Desk. 

 

Marwan Fakih, MD
City of Hope

 

Mary L. (Nora) Disis, MD, FASCO
University of Washington